Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HTR6 | P50406 | 2/20 | 0.55 |
| ▸ | CDK4 | P11802 | 4/20 | 0.50 |
| ▸ | CCND1 | P24385 | 4/20 | 0.50 |
| ▸ | GUSB | P08236 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3177815 | 0.81 | HTR6 (0.65) | KMT2AHTR6CDK4CCND1PLAU | |
| SCHEMBL916458 | 0.81 | HTR6 (0.51) | KMT2AHTR6PLAUCYP11B1CHRNB2 | |
| SCHEMBL7084091 | 0.81 | PLAU (0.50) | HTR6PLAUCYP11B1GRIN2B | |
| SCHEMBL694100 | 0.81 | CYP11B1 (0.43) | KMT2AHTR6GUSBCYP11B1CHRNB2 | |
| SCHEMBL31661458 | 0.81 | PLAU (0.50) | HTR6PLAUCYP11B1GRIN2B | |
| SCHEMBL29509279 | 0.81 | HTR6 (0.73) | KMT2AHTR6CDK4CCND1PLAU | |
| SCHEMBL31021 | 0.81 | HTR6 (0.73) | KMT2AHTR6CDK4CCND1PLAU | |
| SCHEMBL6696139 | 0.81 | KMT2A (0.53) | KMT2AHTR6PLAUCYP11B1HDAC1 | |
| SCHEMBL29643774 | 0.79 | PTK2 (0.49) | KMT2ACYP11B1CHRNB2CHRNA4GABRA5 | |
| SCHEMBL26703942 | 0.79 | HTR6 (0.58) | KMT2AHTR6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815218-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-10407407-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-09-10 | — | — | US | disclosed |
| EP-0949259-B1 | N-HYDROXYUREA DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | NIKKEN CHEMICALS CO LTD (JP) | 2001-06-20 | — | — | EP | disclosed |
| US-6184238-B1 | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | NIKKEN CHEMICALS CO., LTD. (JP) | 2001-02-06 | — | — | US | disclosed |
| EP-0949259-A1 | N-HYDROXYUREA DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Nikken Chemicals Company, Limited (JP) | 1999-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407407-B2 | Benzoimidazole derivatives as PAD4 inhibitors | PADI4, PADI1, PADI2 | KMT2A 1974/4885HTR6 4587/4885CDK4 142/4885 |
| US-10815218-B2 | Benzoimidazole derivatives as PAD4 inhibitors | PADI4, PADI1, PADI2 | KMT2A 1974/4885HTR6 4587/4885CDK4 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.